Director's Dealing

29 November 2024

4basebio plc


(“4basebio” or the "Company")
 

Director’s Dealing

29 November 2024 – 4basebio PLC (AIM: 4BB) (“4basebio” or the “Company”), which develops and commercialises the large-scale manufacture of synthetic DNA as well as nanoparticle delivery solutions, announces that it was informed by Dr. Heikki Lanckriet, CEO of the Company, that he acquired ordinary shares in the Company through the market as follows: 

Name Number of Shares Acquired Price per Share (p) Shareholding Following Acquisition Shareholding as a Percentage of Issued Share Capital
Heikki Lanckriet 12,000 1,315p 1,115,288 7.27%

The issued share capital of the Company comprises 15,477,395 ordinary shares.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 as amended by regulation 11 of the market abuse (amendment) (EU Exit) regulations 2019/310.

Enquiries

4basebio PLC

Dr. Heikki Lanckriet

+44 (0)1223 967 943

Nominated Adviser

Cairn Financial Advisers LLP

Jo Turner / Sandy Jamieson / Ed Downes

+44 (0)20 7213 0880

Joint Corporate Broker

RBC Capital Markets

Rupert Walford / Kathryn Deegan

+44 (0)20 7653 4000

Joint Corporate Broker

Cavendish Capital Markets Limited

Geoff Nash / Nigel Birks

+44 (0)20 7220 0500

Notes to Editors

About 4basebio

4basebio (AIM: 4BB) is an innovation driven life biotechnology company focused on accelerating the development of advanced therapy medicinal products (ATMPs) through its high-performance synthetic DNA products and non-viral, cell targeting nucleic acid delivery platform. The Company’s objective is to become a market leader in the manufacture and supply of high-quality synthetic DNA products for research, therapeutic and pharmacological use as well as development of target specific non-viral vectors for the efficient delivery of payloads in patients.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person closely associated
a. Name Dr. Heikki Lanckriet
2 Reason for notification
a. Position/Status CEO
b. Initial notification/Amendment Initial Notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a. Name 4basebio plc
b. LEI 213800E2DX9EAIUNCB30
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a. Description of the financial instrument, type of instrument

Identification Code
Ordinary Shares

ISIN: GB00BMCLYF79
b. Nature of the transaction Acquisition of ordinary shares
Price(s) per share (p) Volume(s)
1,315p 12,000
d. Aggregated information
  • Volume
  • Price
  • 12,000
  • 1,315 pence per share
e. Date of the transaction 28/11/2024
f. Place of the transaction London Stock Exchange, AIM



Companies

4basebio (4BB)
UK 100

Latest directors dealings